ESR1 and breast carcinoma: Women at high risk for breast cancer are eligible for chemoprevention with selective estrogen receptor modulators or aromatase inhibitors, which have been shown in randomized controlled trials to reduce the incidence of invasive breast cancer by up to 50%-65% (1-6).